Business
GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer
ATLANTA, GA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies
About this update from Geovax Labs, Inc.
[{"type":"text","content":"ATLANTA, GA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- \n via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today the appointment of Mark J. Newman, Ph.D. as Chief Scientific Officer. Dr. Newman, who previously served the company as vice president of research and development from 2010 to 2013, joins GeoVax on a half-time basis. The other portion of his working time will be devoted primarily to his work at NewMark Diagnostics, which he founded in 2016. Prior, he served senior management positions at PaxVax, Pharmexa A/S, Epimmune, Vaxcel, Apollon, and Cambridge Biotech. During his 30-year career he shepherded the development of experimental vaccine and adjuvant products through preclinical research and into Phase 1 & 2 clinical testing. He is widely published in peer review publications and holds 10 U.S. patents. He holds a dual B.Sc/M.Sc. degree in Agriculture and Pre-Veterinary Medicine from the Ohio State University and earned his Ph.D. in Immunology at the John Curtin School for Medical Research, The Australian National University, Canberra. David Dodd, GeoVax President and CEO, commented, “We are delighted to welcome Mark back to GeoVax and look forward to his guidance as we enter this pivotal period in the company’s evolution. His familiarity with the management team and our MVA technology will translate into a rapid integration, for which we are excited. We look forward working with Mark as we embark onto this next exciting phase for GeoVax.” About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the...